ADVERTISEMENT
Sri Lanka
FDA Investigating Disposable Gloves From Hundreds Of Foreign Companies Because Of Reprocessing Fears
The US FDA says it’s “investigating certain imported medical gloves that appear to have been reprocessed, cleaned, or recycled and sold as new.” The 270 firms in question are listed on an import alert that says their gloves are subject to Detention without Physical Examination.
Here’s the complete list of foreign firms that were included on an import alert because gloves they made or sold may have been “reprocessed, cleaned, or recycled and sold as new,” the US FDA says.
Looking to rationalize its Sri Lankan operations, Cipla buys 40% stake held by joint venture partner Citihealth Imports in Cipla Pharma Lanka. Wholly-owned subsidiary Breathe Free Sri Lanka will be its vehicle for growth in the country.
Rational valuations and the potential divestment of older portfolios by foreign firms were some of the key mergers and acquisitions (M&A) trends highlighted by industry experts at a recent congress in India.
US biotech, Visterra, has joined hands with vaccine giant, Serum Institute of India, to take its early stage monoclonal antibody product candidate (VIS513) for dengue forward.
Sri Lanka has implemented plans to encourage local production, with the government undertaking to "buy back" supplies for a number of specified pharmaceutical products.
Dr Reddy's Laboratories has snapped up a select portfolio of UCB's established products business in India, Nepal, Sri Lanka and Maldives for INR8bn ($128m), bolstering its presence in the high growth dermatology, respiratory and paediatric segments.
Sri Lanka's new National Medicines Regulatory Authority Bill has set out a clutch of rules pertaining to the prescription, pricing and registration of medicines - a move some experts say could bring about significant price cuts and pare the number of brands on the market there.
Niche verticals continue to draw private equity interest with Sequoia Capital said to be on course to investing around INR1bn ($16.2m) in the Indian specialty dermatology firm, Curatio Healthcare.
Things may be on the mend in India's clinical research sector, if the measured but hopeful views of Jacob Parambi, vice-president and head of Quintiles India, are anything to go by.